Company Overview: PHM.MC

Upcoming Projects (PHM.MC)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (PHM.MC)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (PHM.MC)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (PHM.MC)

PharmaMar (PHM.MC) Expects Recruitment to Conclude in 2018 for Phase 3 Registration Trial Evaluating Lurbinectedin (PM1183) in Small-Cell Lung Cancer
Ticker: PHM.MC
Occurred on: Jan 18, 2018
PharmaMar (PHM.MC) Expects Data from Phase 3 Registration Trial in H2 2017 Evaluating Lurbinectedin (PM1183) in Platinum-Resistant Ovarian Cancer
Ticker: PHM.MC
Occurred on: Sep 11, 2017
Feedback on aplidin (plitidepsin) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma from the EMA expected in the second half of 2017
Ticker: PHM.MC
Occurred on: Aug 09, 2017
PharmaMar (PHM.MC) Expects CHMP Recommendation in H2 for Aplidin in Multiple Myeloma
Ticker: PHM.MC
Occurred on: Aug 09, 2017
PharmaMar (PHM.MC) Initiates Phase 1 Study Evaluating PM1183 (lurbinectedin) in Certain Types of Unresectable/Advanced Solid Tumors
Ticker: PHM.MC
Occurred on: Nov 28, 2016
PharmaMar (PHM.MC) Presents Data on Yondelis in Different Sarcoma Subtypes at the 21st Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Ticker: PHM.MC
Occurred on: Nov 10, 2016
European Medicines Agency Agrees to Review PharmaMar's (PHM.MC) Marketing Authorization Application (MAA) for Aplidin® (plitidepsin) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)
Ticker: PHM.MC
Occurred on: Oct 28, 2016
PharmaMar (PHM.MC) Completes Enrollment for Phase 3 CORAIL Trial Evaluating PM1183 (lurbinectedin) in Platinum-Resistant Ovarian Cancer
Ticker: PHM.MC
Occurred on: Oct 18, 2016
PharmaMar (PHM.MC) Phase 2 Data Evaluating PM1183 (lurbinectedin) in BRCA 1/2 -Associated Metastatic Breast Cancer Presented at the European Society of Medical Oncology (ESMO) Congress
Ticker: PHM.MC
Occurred on: Oct 10, 2016
PharmaMar (PHM.MC) Expects Interim Analysis in Q2 from the Phase 3 INNOVATYON (IST) Study Evaluating Yondelis in Relapsed Ovarian Cancer
Ticker: PHM.MC
Occurred on: Sep 27, 2016
PharmaMar submits MAA to EMA for Aplidin for the treatment of multiple myeloma
Ticker: PHM.MC
Occurred on: Sep 22, 2016
PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer
Ticker: PHM.MC
Occurred on: Aug 02, 2016
PharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer
Ticker: PHM.MC
Occurred on: Aug 02, 2016
Phase III trial with PM1183 in ovarian cancer (CORAIL) continues on the basis of positive recommendation by IDMC
Ticker: PHM.MC
Occurred on: Feb 08, 2016

Strategic Initiatives (PHM.MC)

PharmaMar (PHM.MC) Enters Exclusive License Agreement in Japan with Chugai Pharma (CHGCY) for Marine-Derived Cancer Candidate PM1183
Tickers: PHM.MC, CHGCY
Announcement Date: Dec 22, 2016
PharmaMar (PHM.MC) Agrees to Licensing Agreement with Boryung Pharm for Aplidin in South Korea
Tickers: PHM.MC, Boryung Pharm
Announcement Date: Oct 04, 2016

PHM.MC Overview